Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for rare melanoma

NCT ID NCT05384496

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs, axitinib and nivolumab, can shrink or control advanced mucosal melanoma that hasn't been treated before. About 20 adults with this rare cancer will receive the combination. The goal is to see if the drugs work better together than alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUCOSAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mucosal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUCOSAL MELANOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Westchester

    RECRUITING

    Harrison, New York, 10604, United States

    Contact Phone: •••-•••-••••